Target
HER2 (ERBB2)
1 product
474 abstracts
Abstract
Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.Org: Nantes University Hospital Center, Azienda Ospedaliero-Universitaria San Luigi Gonzaga,
Abstract
Defining low-HER2 cancers using RNA quantification by next generation sequencing.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Medical Center, NJ, Genomic Testing Cooperative, Irvine,
Abstract
Prevalence of recreational and medical cannabis products in Veterans and their interactions with cancer directed pharmacological treatment.Org: University of Tennessee Health Science Center, University of Tennessee of Health Science Center, Kirkland Cancer Center, Baptist Memorial Hospital - Collierville, Lt. Col. Luke Weathers Jr. VA Medical Center,
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.Org: Greenwich LifeSciences, Stafford, TX, Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Org: Daiichi Sankyo Co, Ltd., Daiichi Sankyo Inc.,
Abstract
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.Org: NSABP, Dana-Farber Cancer Institute, University of Michigan Health System Comprehensive Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Institute of Cancer Research,
Abstract
Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).Org: Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, The Third Hospital of Shandong Province, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Yantai Yuhuangding Hospital,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.Org: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, Harbin Medical University Cancer Hospital, Harbin, China, Chongqing University Cancer Hospital, Chonqqing, China, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,
Abstract
Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.Org: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, Precision Medicine in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Fondazione Pascale, Naples, Italy, Sapienza University of Rome, Medical Oncology Department, Policlinico Umberto I, Roma, Italy,
Abstract
Effect of placental circulating T cells expressing CD16 on multiple hematological and solid tumor cancers through combination with various monoclonal antibodies.Org: Celularity Inc.,
Abstract
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group,
Abstract
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.Org: LMU University Hospital Munich, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, West German Study Group, Ev. Hospital Bethesda,
Abstract
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.Org: Hangzhou HighField Biopharmaceuticals Corporation, Zhejiang University, School of Pharmacy,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.Org: Cancer Research @UCC, Brown University - ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Saint Vincent Hospital Cancer Center Green Bay, University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.Org: H. Lee Moffitt Cancer Center and Research Institute, Roswell Park Comprehensive Cancer Center,
Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Universidad Europea de Madrid,
Abstract
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.Org: Centre Léon Bérard, Centre Hospitalier de l'Ardenne - Site de Libramont, Centre Oscar Lambret, Institut Curie, Saint Cloud, France, CHU Liège and Liège University,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Maria Sklodowska-Curie National Research Institute and Oncology Centre (MSCI), Warsaw, Poland, Hospital Clínico San Carlos and IdISSC, Madrid, Spain,
Abstract
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).Org: Zymeworks BC, BeiGene Ltd.,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).Org: Department of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan, Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan, Department of Oncology, Sagara Hospital, Kagoshima, Japan, Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan, Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan,
Abstract
Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Istituto Europeo di Oncologia, IRCCS and University of Milano, Aichi Cancer Center Hospital, Seoul National University Hospital,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,
Abstract
Patient-derived tumor cell clusters (PTC) guiding-neoadjuvant therapy of HER2-positive breast cancer: A prospective randomized phase II clinical trial.Org: Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.Org: Sarah Cannon Research Institute/Tennessee Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Cancer Center, Sun Yat-sen University, Guangzhou, China, Shantou Central Hospital, Shantou, China,
Abstract
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Org: Dana-Farber Cancer Institute, Yale School of Medicine, University of Pittsburgh Medical Center (UPMC), Yale Cancer Center, Harvard Medical School,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.Org: University of California, San Francisco, Miami Cancer Institute, Baptist Health South Florida, Mayo Clinic, Rush University Medical Center,
Abstract
ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.Org: Institut Curie, Saint Cloud, France, Paris and Saint Cloud, France, Centre Oscar Lambret, Lille University Hospital,
Abstract
A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Memorial Sloan Kettering Cancer Center,
Abstract
Neoadjuvant targeted therapy in early resectable HER2-mutant lobular breast cancer.Org: Vanderbilt-Ingram Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, UT Southwestern Simmons Comprehensive Cancer Center,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).Org: Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Lombardi Cancer Center Georgetown University, Regional Cancer Care Associates, Cantex Pharmaceuticals, Georgetown University Medical Center,
Abstract
Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine and Fred Hutchinson Cancer Center, University of Pittsburgh, Washington University School of Medicine, Kaplan Hospital,
Abstract
Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.Org: West German Study Group, Moenchengladbach, Germany, Queen Mary University of London, London, United Kingdom, Medical School Brandenburg, Institute for Biometrics and Registry Research, Neuruppin, Neuruppin, Germany,
Abstract
Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.Org: Department of Breast Surgery, Sun Yat-sen Memorial Hospital, 2nd Hospital, Zhejiang University School of Medicine, Department of Medical Oncology, Xuzhou Central Hospital,
Abstract
The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study).Org: National Center for Global Health and Medicine, Shimane University Hospital, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer.Org: Genor Biopharma Co.,Ltd., Genor Biopharma, Genor Biopharma Co.,Ltd., Shanghai, China, Genor Biopharma Co., Ltd., Beijing, China,
Abstract
Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd).Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NYU Grossman Long Island School of Medicine, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center,
Abstract
Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials.Org: The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, CT, BronxCare Health System, The Bronx, NY, Samaritan Medical Centre,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).Org: Division of Hematology/Oncology, Department of Internal Medicine Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital; Cancer Research Institute, Seoul National University, Jongno-Gu, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang-Si, South Korea, Division of Hematology/Oncology, Department of Internal Medicine Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of (South), Korea University Anam Hospital, Seoul, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, South Korea, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Deparment of Medical Oncology, Yonsei Unviersity College of Medicine, Gangnam Severance Hospital, Seoul, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, South Korea, Division of Hematology-Oncology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea, Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).Org: Kanagawa Cancer Center, Fukushima Medical University, School of Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Shizuoka General Hospital,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors.Org: Iambic Clinical Advisory Board,
Abstract
Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.Org: Surgery Department, Institut Curie, Saint Cloud, France, Universite Paris Cite, Residual Tumor and Response to Treatment, U932 Immunity and Cancer,
Abstract
A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.Org: Division of Hematology/Oncology, University of Cincinnati Cancer Center,
Abstract
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.Org: University of Hawaii Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center,
Abstract
Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Primary analysis of a prospective, multicenter, response-adapted study.Org: Second Hospital of Shandong University, Jinan, China, Affiliated Hospital of Jining Medical University, Jining, China, Binzhou Medical University Hospital, Binzhou, China, Linyi Cancer Hospital, Linyi, China, Liaocheng People's Hospital, Liaocheng, China,
Abstract
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.Org: Adelaide Cancer Center, ICON Cancer Care, Austin, TX, Adelaide Cancer Center, Brisbane, Australia,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.Org: Mayo Clinic Florida, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Safety and efficacy of biosimilar TDM-1: A real world retrospective study.Org: Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad,
Abstract
Use of IL-3RB to mediate antitumor effect of CAR-T cells through the JAK-STAT signaling pathway.Org: Thoracic Oncology Ward, Institute of Medical Technology, Peking University Health Science Center, Beijing NA,
Abstract
Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study.Org: Blacktown Hospital, Hollywood Private Hospital, Liverpool Hospital, Alphamab Oncology Ltd.,
Abstract
Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).Org: Division of Medical Oncology, Hyogo Cancer Center, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Department of Clinical Oncology, St. Marianna University School of Medicine, Clinical Research Center, Kindai University Hospital, Kindai University Hospital Cancer Center,
Abstract
Deciphering tumor microenvironment dynamics in HER2-amplified refractory metastatic colorectal cancer in the TRIUMPH trial.Org: Hiroshima University Hospital, Department of Surgery, NHO, Osaka National Hospital, Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center,
Abstract
Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).Org: Reggio Emilia, Potenza, Italy - Reggio Emilia, Vimercate, Experimental Clinical Abdominal Oncology Unit,
Abstract
Evaluating antitumor activity and response determinants to trastuzumab deruxtecan in pediatric solid tumors.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.Org: The First Affiliated Hospital of Xi'an Jiaotong University,
Abstract
Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial.Org: The First People's Hospital of Xiangtan City, Xiangtan, ShaoYang Central Hospital,
Abstract
A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.Org: University Cancer Center Germany, St. Anna Hospital Herne, RKH-Clinics Ludwigsburg, University Hospital Ulm, Charité-University madicine Berlin,
Abstract
Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).Org: IRCCS San Raffaele Hospital and Scientific Institute, Division of Hematology/Oncology, UCLA David Geffen School of Medicine,
Abstract
Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study.Org: Imaging Department, Jiangsu Cancer Hospital Medical Oncology, Jiangsu Cancer Hopistal,
Abstract
Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine.Org: South Carolina Oncology Associates,
Abstract
Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ, Highlands Oncology Group, South Carolina Oncology Associates, Integra Connect,
Abstract
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.Org: Azienda Ospedaliera Universitaria Pisana, Veneto Institute of Oncology - IRCCS, San Bortolo General Hospital, CRO Aviano, Fondazione Poliambulanza,
Abstract
CNS efficacy of trastuzumab deruxtecan in metastatic breast cancer: A single-institution, real-world analysis.Org: UC San Diego, UC San Diego Moores Cancer Center,
Abstract
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, University of Michigan,
Abstract
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.Org: Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Department I of Thoracic Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Tottori University Hospital, University Hospital KU Leuven,
Abstract
Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.Org: BC Cancer-Vancouver Centre, University of British Columbia,
Abstract
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.Org: Department of Abdominal and Pelvic Medical Oncology, The First People's Hospital of Tianmen City, Affiliated Hospital of Hubei Technology College, Tianmen, China,
Abstract
Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.Org: Tianjin Cancer Hospital Airport Hospital,
Abstract
FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study.Org: Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Shanxi Provincial People's Hospital,
Abstract
Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study.Org: Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People’s Hospital,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Predictors of cardiotoxicity in patients with early breast cancer treated with doxorubicin and/or trastuzumab: Implications of race/ethnicity and insurance status.Org: Advocate Aurora Health, Milwaukee, WI,
Abstract
Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.Org: Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, Belgium, Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan, Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, Center of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland, Astellas Pharma Global Development, Inc., Northbrook, IL,
Abstract
Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer.Org: Providence Cancer Institute,
Abstract
Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.Org: Department of Thyroid and Breast Surgery, Quzhou People's Hospital, Quzhou, China, Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, Department of Breast Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, Ruian People's Hospital, Ruian, China, Department Of Thyroid And Breast Surgery, Wenzhou Central Hospital, Wenzhou, Zhejiang, China,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02).Org: Hadassah Medical Moscow, Srinagarind Hospital, Chris O’Brien Lifehouse,
Abstract
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).Org: Next Oncology Virginia and Virginia Cancer Specialists, Henry Ford Cancer Institute, Detroit, MI, UC Davis Comprehensive Cancer Center, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Henan Cancer Hospital,
Abstract
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Seoul National University Hospital, Cancer Research Institute, Seoul, South Korea, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.Org: Affiliated Cancer Hospital of Chongqing University,
Abstract
Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.Org: Huadong Medicine Co., Ltd, Huadong Global Development Center, HangZhou ZhongMei HuaDong Pharmaceutical Company,
Abstract
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.Org: National Cancer Center East, Daiichi Sankyo Ltd.,
Abstract
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).Org: Chang Gung Memorial Hospital Linkou Branch, Kuala Lumpur Hospital, Siriraj Hospital, Precision Medicine Asia, PREMIA Holdings (HK) Limited,
Abstract
Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4/6 inhibitors in HER2-low breast cancer.Org: The Second Clinical College of Guangzhou University of Chinese Medicine,
Abstract
Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).Org: The GOG Foundation, Inc., Women and Infants Hospital, Brown University, Spectrum Health Cancer Center, LSU Health School of Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine,
Abstract
Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis.Org: Catholic University of Pelotas, RS, Brazil, Pelotas, Brazil, Universidade Estadual do Centro Oeste (UNICENTRO), Guarapuava, Brazil, Federal University of Amazonas - UFAM, Manaus, Brazil, University of Brasilia, Brasilia, Brazil,
Abstract
Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.Org: School of Life Science and Technology, Tonji Univesity,
Abstract
Evaluating the correlation between expression levels of carboxyl terminal modulator protein (CTMP) and the efficacy of trastuzumab in Syrian patients with HER2+ metastatic breast cancer.Org: Damascus University, Syrian Arab Republic,
Abstract
Clinical efficacy of pyrotinib combined with stereotactic radiosurgery in HER2-positive breast cancer brain metastases.Org: Guanghzou, China,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).Org: Maria Skłodowska-Curie National Research Institute and Oncology Centre, Hôtel-Dieu de Québec, Clinical Hospital “RZHD-Medicine”, Chi Mei Medical Center,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.Org: Jagiellonian University Medical College Hospital, Kraków, N.N Blokhin National Medical Research Center of Oncology, Reinier de Graaf Gasthuis, Delft,
Abstract
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.Org: Oncology Unit Santa Maria delle Croci Hospital, Cardinale G Panico, Azienda Toscana Nord Ovest, University Hospital of Pisa,
Abstract
A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors.Org: Department of Breast Medical Oncology, Fujian Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, First Affiliated Hospital of Wannan Medical College, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.Org: Boehringer Ingelheim (Canada) Ltd,
Abstract
Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial.Org: First Hospital of China Medical University,
Abstract
Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics.Org: Saint Joseph University of Beirut, Hotel-Dieu de France,
Abstract
Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study.Org: Air Force Medical University,
Abstract
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.Org: National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Internal Medicine-Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Shanxi Provincial Cancer Hospital, Taiyuan, China,
Abstract
Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer?Org: Ilboza medical, Uzbekistan,
Abstract
Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Molecular Oncology,
Abstract
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer.Org: Department of Thyroid, Breast, and Vascular Surgery at Xijing Hospital, Air Force Medical University,
Abstract
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, Quantum Leap Healthcare Collaborative,
Abstract
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.Org: Samsung Medical Centre, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Memorial Sloan Kettering Cancer Center,
Abstract
A propensity-matched analysis of the efficacy and safety of neoadjuvant inetetamab and pertuzumab with paclitaxel and carboplatin (TCbIP) on locally advanced HER2-positive breast cancer.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Molecular Oncology,
Abstract
The relationship between PIK3CA mutations and survival in patients with human epidermal growth factor receptor 2–positive breast cancer receiving pyrotinib combined with trastuzumab for neoadjuvant treatment.Org: the Eighth Medical Center of Chinese PLA General Hospital,
Abstract
Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.Org: Shangyu People's Hospital, Shaoxing, China,
Abstract
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).Org: Hospital of Xinjiang Production and Construction Corps,
Abstract
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.Org: Berry Consultants, LLC, Seagen, Cleveland Clinic Taussig Cancer Instititute, Yale School of Medicine, University of California Irvine,
Abstract
HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors.Org: Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development,
Abstract
Natural products to enhance anti-tumor effects of trastuzumab and paclitaxel on the SKBR3, which is human breast cancer cell line.Org: Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, Izmir International Biomedicine and Genome Institute, Department of Medical Pharmacology, Department of Medical Biology and Genetics,
Abstract
Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases.Org: Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.Org: Hangzhou Adcoris Biopharma Co., Ltd,
Abstract
Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer.Org: University of Colorado Health Cancer Care, University of Colorado Cancer Center, Louisiana State University Health Sciences Center Shreveport, University of Wisconsin, Mount Sinai Medical Center,
Abstract
Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41.Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center,
Abstract
HER2 low hormone positive breast cancer: Unveiling the driver.Org: Medical Research Institute, University of Alexandria,
Abstract
Optimal neoadjuvant treatment and prognostic factors in patients with HR-positive/HER2-positive early or locally advanced breast cancer: A national real-world study in China.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China,
Abstract
A prospective phase II study of neoadjuvant therapy guided by personalized drug-testing on patient-derived tumor-like cell clusters for early breast cancer.Org: College of Future Technology Peking University, Peking University People's Hospital Breast Center,
Abstract
Trastuzumab-induced cardiotoxicity in patients with metastatic HER2-positive breast cancer treated at a reference hospital in Mexico.Org: Hospital de Oncologia Centro Medico Nacional Siglo XXI,
Abstract
Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Clinicopathological characteristics and outcomes of patients with HER2-low breast cancer: 6-year ambispective cohort study from India.Org: Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Kasturba Medical College, Udupi, Manipal University Kasturba Medical College Manipal,
Abstract
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.Org: Department of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Sapporo, Japan, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China,
Abstract
Outcome with pertuzumab, docetaxel, and trastuzumab (PTH) regimen in patients with HER2 positive metastatic breast cancer: Real-world data from a single center in India.Org: Associate Consultant,
Abstract
[68Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease.Org: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, Affibody AB, Stockholm, Sweden, Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden,
Abstract
Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan.Org: Miami Cancer Institute, Baptist Health South Florida, Guardian Research Network,
Abstract
A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma.Org: Leiden, Netherlands, 250 Euston Road, Chordoma Foundation,
Abstract
A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing.Org: Minimally Invasive Therapy Center,
Abstract
Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study.Org: The First Hospital of Chongqing Medical University Affiliated Hospital, Zhangjiakou First Hospital, Guiyang Maternal and Child Health Hospital, Yancheng First People's Hospital,
Abstract
Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer.Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, Stanford University School of Medicine,
Abstract
Peony exploratory analyses of biomarker changes: From baseline to surgical samples in patients with HER2+ breast cancer.Org: Roche (China) Holding, Ltd., Product Development Oncology (PDO) at Roche Product Development,
Abstract
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.Org: Mary Crowley Cancer Research Center, Guangdong Lung Cancer Institute, Valkyrie Clinical Trials, Inc, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.,
Abstract
Efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer.Org: The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China,
Abstract
A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC).Org: SUNY Upstate University Hospital, SUNY Upstate Medical University, SUNY Upstate Medical Center,
Abstract
Triple combination treatment of trastuzumab, chemotherapy and immune checkpoint inhibitor in HER2 positive unresectable, locally advanced, metastatic gastric and esophageal adenocarcinoma: A systematic review and meta-analysis.Org: Quezon City, Philippines,
Abstract
Predicting epirubicin response in Danish patients with breast cancer.Org: Aida Oncology, Dragor, Denmark, JADBio, Crete, Greece, Raven Biosciences,
Abstract
Clinical outcomes of patients with HER2-positive microinvasive breast cancer.Org: Department of Oncology, National Taiwan University Hospital, Asan Medical Center, University of Ulsan College of Medicine, Division of Breast Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.Org: Mayo Clinic, Mayo Clinic Department of Oncology,
Abstract
A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC).Org: SUNY Upstate University Hospital, SUNY Upstate Medical University, SUNY Upstate Medical Center,
Abstract
Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.Org: Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom, The Institute of Cancer Research, London, United Kingdom, The Institue of Cancer Research, London, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom,
Abstract
Identifying mutations in ctDNA to predict antibody-drug conjugate response in breast cancer.Org: UT Southwestern Medical Center, Dallas, TX,
Abstract
Characterization of HER2 alterations in lung adenocarcinoma.Org: Temple University Hospital,
Abstract
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,
Abstract
Efficacy and toxicity of trastuzumab emtansine among patients with HER-2-positive metastatic breast cancer in Saudi Arabia.Org: King Faisal Specialist Hospital and Research Center, Alfaisal University College of Medicine, HCA Houston Healthcare Kingwood/University of Houston,
Abstract
T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study.Org: National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Shougang Beijing University Hospital,
Abstract
Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer.Org: University of Kansas School of Medicine - Wichita,
Abstract
Heterogeneity of immune status in patient-derived malignant pleural effusion and ascites: Relationship to the ex-vivo efficacy of a HER2-targeted tri-specific antibody and a novel cytokine fusion protein.Org: Nanjing JSIAMA Biopharmaceuticals Ltd, Nanjing JSIAMA Biopharmaceuticals Ltd., K2 Oncology Co. Ltd.,
Abstract
The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.Org: Peking University Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).Org: Keck Medical Center of University of Southern California,
Abstract
Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Org: West China Hospital, Sichuan University, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology,
Abstract
Effect of fructose on anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: New roles of sweeteners in cardio-oncology.Org: Fondazione G. Pascale, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella,
Abstract
Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).Org: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Urology, National Cancer Center & National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, General Internal Medicine, Beijing, China, Cancer Hospital of HuanXing ChaoYang District Beijing, Beijing, China, Urinary Surgery Center, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status.Org: nference Inc., AstraZeneca LLC,
Abstract
Clinical significance of HER2 expression between primary tumors and metastatic lymph nodes in patients with extramammary Paget's disease.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangdong Provincial Clinical Research Center for Cancer, Department of Urology Oncological Surgery, Chongqing University Cancer Hospital,
Abstract
Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Xiangya Hospital of Central South University, Changsha, China, Central South University, Changsha, China,
Abstract
Multiomic analysis in ovarian clear cell carcinoma to gain insight into biology and therapeutic opportunities.Org: Portland,OR,
Abstract
Influence of neoadjuvant regimen on the prognosis of locally advanced gastric and gastroesophageal junction cancer with HER2 overexpression.Org: Cancer Hospital Affiliated to Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hosptal,
Abstract
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.Org: Cancer Hospital Affiliated to Shanxi Medical University, General Internal Medicine,
Abstract
Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceutials, Inc., Tariffville, CT,
Abstract
Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceuticals Inc.,
Abstract
The frequency of HER2-low breast cancer among BRCA1, BRCA2, and PALB2 mutation carriers.Org: Hospital of University of Pennsylvania,
Abstract
Metabolic changes due to dexamethasone premedication in patients with breast cancer.Org: ICESP,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.Org: National Cancer Center Hospital Japan East, St. Marianna University School of Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Seoul National University College of Medicine, HonorHealth Research Institute,
Abstract
Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal Univerity of Rio de Janeiro, DASA Oncologia, Federal University of Ceará, Clion Clínica de Oncologia, Hospital São Domingos,
Abstract
Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study.Org: Guizhou University of Traditional Chinese Medicine, Affiliated Hospital of Zunyi Medical University, Department of Oncology, Guizhou Provincial People's Hospital, Zunyi Medical University, Department of Breast Surgery, Guizhou Provincial People's Hospital,
Abstract
Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.Org: Dana-Farber Cancer Institute, Unidad Oncologica de Neuquen, Cooperative Oncological Group of Sur, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.Org: Fudan University Shanghai Cancer Center, China National Biotec Group, West China Hospital, Chengdu Origen Biotechnology, Department of Preventive Medicine,
Abstract
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.Org: Westwood, Kansas City, Department of Biostatistics & Data Science, Central Care Cancer Ctr, The University of Kansas Cancer Center,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,
Abstract
Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).Org: Aichi Cancer Center Hospital, Osaka University Graduate School of Medicine, Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Toranomon Hospital, St. Marianna University Hospital,
Abstract
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Org: Harvard Medical School, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.Org: University of California Comprehensive Cancer Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA, University of Texas MD Anderson Cancer Center, Houston, TX, UC Davis, Davis, CA, Masonic Cancer Center, Minneapolis, MN,
Abstract
ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.Org: Exact Sciences Corporation, Genomic Health Inc, Fred Hutchinson Cancer Research Center, Tisch Cancer Institute, Fox Chase Cancer Center,
Abstract
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).Org: Guardant Health, Inc., Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,
Abstract
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.Org: School of Biotechnology, Medical Oncology Department, CCRT/The Caroline Foundation, Galway University Hospital, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.Org: Memorial Sloan Kettering Cancer Center, Kanagawa Cancer Center, Severance Hospital, Hospital Clinic de Barcelona, Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.Org: Institute of Pathology, University of Regensburg, Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Mindpeak GmbH, Institute of Pathology, Clinical Center Osnabrueck, Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Germany, Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany, Pathologie, Universitätsklinikum Heidelberg, Heidelberg, Germany, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, Munich, Germany, Goethe-Universität Frankfurt, UCT-Frankfurt-Marburg, Frankfurt, Germany, Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany, SRH Waldklinikum Gera GmBH, Gera, Germany, Institut für Versorgungsforschung, Koblenz, Germany, Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland, Gynäkologie, Rotkreuzklinikum München, München, Germany, HELIOS Clinic Berlin-Buch, Berlin, Germany, University Hospital Frankfurt, Frankfurt Am Main, Germany, Department of Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany, German Breast Group GmbH, Neu-Isenburg, Germany, German Breast Group (GBG), Neu-Isenburg, Germany, German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany, Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany,
Abstract
Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.Org: American Oncology Network Pharmacy, Fort Myers, FL,
Abstract
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.Org: Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Chris O'Brien Lifehouse, Royal North Shore Hospital, Sydney, Australia, Westmead Cancer Care Centre,
Abstract
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Cancer Center Hospital East, Kashiwa, Japan, Cedars-Sinai Cancer Institute,
Abstract
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.Org: BeiGene (Shanghai) Co., Ltd., The Fifth Medical Center of Chinese PLA General Hospital,
Abstract
Outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis based on the 21-gene recurrence score.Org: Icahn School of Medicine at Mount Sinai Morningside-West, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022.Org: David Geffen School of Medicine at the University of California,
Abstract
Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).Org: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, Seoul National University Hospital, Jongno-Gu, South Korea, Korea University Anam Hospital, Seoul, South Korea, Samsung Medical Center, Seoul, South Korea,
Abstract
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Org: Université de Montréal, McGill University Health Center, Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Génomique fonctionnelle, CNRS, University of MontpellierOncology, Institute of Oncology Ljubljana,
Abstract
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Liaoning, China,
Abstract
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Department II of breast, Linyi Cancer Hospital,
Abstract
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.Org: University of Miami Hospital/Jackson Memorial Hospital, Ecua-american Laboratories, Hospital de los Valles,
Abstract
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,
Abstract
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.Org: Mayo Clinic, University Hospitals Gasthuisberg Leuven, KU Leuven, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Abstract
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center/NewYork-Presbyterian,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial.Org: West German Study Group, Moenchengladbach, Germany, Klinikum Dortmund gGmbH, Medical School Hannover,
Abstract
Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy.Org: Medical Oncology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Laboratorio di Oncologia Traslazionale, Fondazione Arco Cuneo, Cuneo, Italy, Medical Oncology, AO S. Croce e Carle, Cuneo, Italy, Breast Unit AO S. Croce e Carle, Cuneo, Italy, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Candiolo, Italy,
Abstract
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).Org: Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Dana-Farber Cancer Institute, AstraZeneca, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering - Breast and Imaging Center, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).Org: H. Lee Moffitt Cancer Center and Research Institute, Vaccinex, Inc.,
Abstract
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.Org: H. Lee Moffitt Cancer Center and Research Institute, Ohio State University Wexner Medical Center, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Roswell Park Comprehensive Cancer Center, University of Washington, Cancer Vaccine Institute,
Abstract
Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Shanghai Medical College, Fudan University,
Abstract
Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer.Org: Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Queen Elizabeth Hospital, Hong Kong Sanatorium & Hospital,
Abstract
Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer.Org: Duke University Cancer Institute, Seagen, Inc., Genesis Research, Winship Cancer Institute, Emory University School of Medicine,
Abstract
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.Org: DFCI/BWH Cancer Center, University of Chicago, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Rutgers Cancer Institue of New Jersey, University of Toronto,
Abstract
Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).Org: Flatiron Health, San Francisco, CA,
Abstract
Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.Org: Samsung Medical Center, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg,
Abstract
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.Org: Stanford Hospital & Clinics, Department of Management Science and Engineering, Stanford University School of Medicine, Department of Health Policy,
Abstract
Use and value of self-management (SM) recommendations in a real-world evidence study evaluating digital patient monitoring (DPM) of patients (pts) receiving cancer care.Org: University of Lausanne, School of Health Sciences, University of Skövde, University of Applied Sciences and Arts Western Switzerland, Careum School of Health, F. Hoffmann-La Roche Ltd,
Abstract
Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.Org: UNC Lineberger Comprehensive Cancer Center/University of Milan, University of North Carolina at Chapel Hill, Department of Medicine, University of North Carolina at Chapel Hill, University of North Carolina/Lineberger Comprehensive Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
NRG1 fusions in solid tumors.Org: Caris Life Sciences, Irving, TX, Caris Life Sciences Research and Development, West Cancer Center and Research Institute,
Abstract
The worldwide impact of HER2-targeted treatments in women with breast cancer: An epidemiological modeling study.Org: Genentech Inc., F. Hoffmann-La Roche AG,
Abstract
Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor–positive breast cancer.Org: Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University of Florida College of Medicine Jacksonville,
Abstract
Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.Org: National Taiwan University Hospital Yunlin Branch, National Taiwan University College of Medicine,
Abstract
Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Weill Cornell Medicine/New York Presbyterian Hospital,
Abstract
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.Org: The Fourth Hospital of Hebei Medical University, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, West China Hospital, Shuwen Biotech Co. Ltd.,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center Medical, Cedars-Sinai Cancer, Cedars-Sinai Cancer Beverly Hills, Cedars-Sinai Cancer Tarzana,
Abstract
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.Org: University of Florida College of Medicine Jacksonville, University of Florida College of Public Health and Health Professions, Francis H. Burr Proton Center, Orlando Health Cancer Institute,
Abstract
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.Org: University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hämatologisch-Onkologische Praxis Eppendorf (HOPE) and University Cancer Center Hamburg (UCCH), Department of Internal Medicine IV, University Hospital Halle, Hematology Oncology Practice Eppendorf,
Abstract
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.Org: Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Guardant Health, Inc., Palo Alto, CA, Redwood City, CA,
Abstract
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Peking University First Hospital, Affiliated Drum Tower hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Cancer Vaccine Institute, University of Washington Medical Center,
Abstract
FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.Org: Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Shanghai, China, Shanghai Fosun Pharmaceutical Development Co., Ltd., Fosun Pharma USA, Inc,
Abstract
Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, University of Chicago Department of Public Health Sciences, Center for Data Intensive Science at the University of Chicago, Department of Medicine, University of Chicago,
Abstract
HER2-low breast cancer brain metastases: Incidence and treatment implications.Org: University of Toronto, Sunnybrook Hospital, Toronto, ON, Canada, Sunnybrook Health Sciences Center, Department of Laboratory Medicine and Pathobiology,
Abstract
Impact of HER2 assay sensitivity on the ability to detect tumors with low to ultra-low HER2 expression: A TMA study on more than 10,000 tumors from more than 100 tumor entities.Org: University Medical Center Hamburg-Eppendorf, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Academic Hospital Fuerth,
Abstract
Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort.Org: National University Hospital, National Cheng Kung University Hospital, Queen Elizabeth Hospital, Seoul National University Hospital, Westmead Hospital,
Abstract
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.Org: Roswell Park Comprehensive Cancer Center, Buffalo, IL, Nykode Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital,
Abstract
Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.Org: H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffit Cancer Center,
Abstract
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.Org: Mayo Clinic, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Rochester Medical Center Department of Medical Oncology, Loyola University Medical Center, Vanderbilt University Medical Center,
Abstract
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.Org: Duke Cancer Institute, Dana-Farber Cancer Institute, The Oncology Institute of Hope and Innovation, Suzhou Zanrong Pharma,
Abstract
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.Org: Stephenson Cancer Center at the University of Oklahoma, Macquarie University Cancer Institute, Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Hunan Provincial People's Hospital, Changsha, China, Linyi Cancer Hospital,
Abstract
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.Org: Genome Insight Inc., Samsung Medical Center, Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Research Institute for Future Medicine,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Comprehensive characterization of androgen receptor expression in breast cancer.Org: Caris Life Sciences, Irving, TX, City of Hope National Medical Center, Washington University School of Medicine in St Louis, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.Org: Greenwich LifeSciences, Stafford, TX, Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine,
Abstract
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).Org: Fudan University Shanghai Cancer Center, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Breast Oncology, Peking University Cancer Hospital, Harbin Medical University Cancer Hospital,
Abstract
The impact of the 4R Oncology model of team-based care delivery on timing and sequence of guideline recommended interdependent care in breast and lung cancers.Org: Center for Business Models on Healthcare, Glencoe, IL, Genentech Inc, South San Francisco, CA, Albert Einstein College of Medicine, Bronx, NY, Northwestern University Feinberg School of Medicine, Chicago, IL,
Abstract
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.Org: City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, The Sarah Cannon Research Institute, Knight Cancer Institute, Cedars-Sinai Cancer Center,
Abstract
Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer.Org: University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, ICES, Sunnybrook Odette Cancer Centre,
Abstract
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.Org: Helios Klinikum Berlin-Buch, Dana-Farber Cancer Institute, International Breast Cancer Center, Quiron Group, Practice for Hematology and Internal Oncology, Latin American Cooperative Oncology Group (LACOG),
Abstract
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, NEXT Oncology - Virginia Cancer Specialists, University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute,
Abstract
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,
Abstract
Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes.Org: Medical College of Wisconsin, Froedtert and the Medical College of Wisconsin Workforce Health, Milwaukee, WI,
Abstract
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, START Midwest, Grand Rapids, MI, Valkyrie Clinical Trials, Inc, Stanford Hospital & Clinics, Virginia Cancer Specialists,
Abstract
Can synthetic data accurately mimic oncology clinical trials?Org: CHEO Research Institute, Replica Analytics, Ottawa Hospital Research Institute, McMaster University and Juravinski Cancer Centre, University of Ottawa,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Gustave Roussy Cancer Center, ICO Institut de Cancerologie de l'Ouest, Oscar Lambret Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France,
Abstract
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.Org: University of California San Diego Medical Center, La Jolla, CA, Wake Forest University School of Medicine, University of California San Francisco, University of Rochester Medical Center Department of Medical Oncology, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Breast Medicine Service, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China,
Abstract
MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.Org: Dallas Surgical Group, Bon Secours Cancer Institute at St. Francis, Yale University, Lenox Hill Hospital, Northwell Health, New Hyde Park, NY,
Abstract
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California Irvine, MD Anderson Hematology/Oncology Fellowship, The Medical College of Wisconsin,
Abstract
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.Org: NeoGenomics Ltd, Cambridge, United Kingdom, Medipole Lyon Villeurbanne, Villeurbanne, France, Infirmerie Protestante, Caluire Et Cuire, France, Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Impact of race on BluePrint genomic subtyping in HER2+ breast cancer.Org: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Division of Epidemiology and Community Health, Department of Medicine, Icahn School of Medicine at Mount Sinai, Vanderbilt Epidemiology Center,
Abstract
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.Org: Nottingham Univ City Hosp NHS Trust, Van Geest Cancer research Centre, School of Science and Technology Nottingham Tr, Nottingham University Hospitals NHS Trust, Nottingham Trent University,
Abstract
Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.Org: Gangnam Severance Hospital, Yonesi University College of Medicine, Seoul National University Hospital, Asan Medical Center, Center for Breast Cancer,
Abstract
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).Org: Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, University of Victoria, Victoria, BC, Canada, Canadian Cancer Society, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Patient Partner, Toronto, ON, Canada, University of Alberta, Edmonton, AB, Canada, BC Cancer/ University of British Columbia, Vancouver, BC, Canada, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Department of Medicine, Icahn School of Medicine at Mount Sinai, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre,
Abstract
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.Org: University of Texas Southwestern Medical Center, Clion - CAM Group, Cedars-Sinai Medical Center, Cancer Care Assoc-TMPN, Cancer Care Associates of York,
Abstract
Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.Org: Fudan University Shanghai Cancer Center, Cancer Institute of Jiangsu Province, Shanghai Medical College, Fudan University, The Fourth Hospital of Hebei Medical University, The First Hospital of Jilin University, Changchun, Jilin Province, China,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.Org: National Cancer Center Hospital East, Kashiwa, Japan, Chuo-Ku, Japan, Department of Laboratory Medicine and Pathology, University of Washington, Tokyo, Japan, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.Org: Comprehensive Cancer Center - Universitätsklinik für Frauenheilkunde Medizinische Universität Wien / AKH, Medical University of Vienna, Dept of OB/GYN, Karl Landsteiner Medical University, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, Department of Oncology, Medical University of Graz,
Abstract
Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis.Org: Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China, Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, 350001, China, Fujian Center for Disease Control and Prevention, Fuzhou, Fujian, China, Johns Hopkins University, Baltimore, MD,
Abstract
Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB).Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Homi Bhabha cancer hospital and research centre, Tata Memorial Center (HBNI),
Abstract
Implementation of a streamlined prior authorization process to improve cancer care delivery.Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY,
Abstract
Advancing individualized care in advanced gastroesophageal cancers (GEC): A quality improvement initiative.Org: Massachusetts General Hospital, PRIME Education LLC,
Abstract
Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, Chi Mei Chest Hospital, Department of Oncology, National Cheng Kung University Hospital, Blacktown Hospital, St. George Hospital,
Abstract
Prognostic factors in hormone receptor positive oligometastatic breast cancer.Org: Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département d’Oncologie médicale, Institut Claudius Regaud, IUCT - Oncopole,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,
Product
TMZAbstract
Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Chonnam National University Medical School and Hwasun Hospital,
Abstract
Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.Org: Loma Linda University Medical Center, Loma Linda University Department of Radiation Technology, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Loma Linda University School of Medicine, Loma Linda University Cancer Center,
Abstract
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,
Abstract
SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial.Org: Queen's University Belfast, University of Cambridge, University of Oxford, Western General Hospital, University of Birmingham,
Abstract
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).Org: Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Department of Surgery and Cancer Research Institute, Seoul National University, College of Medicine, Seoul, South Korea, Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea, Gangnam Severance Hospital, Seoul, NA, Korea, Republic of (South), Division of Breast, Department of Surgery , College of Medicine, University of Ulsan, Seoul, South Korea,
Abstract
Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.Org: University of Padua School of Medicine, Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Montefiore Medical Center, Albert Einstein College of Medicine, UOSD Hereditary Tumors, Veneto Institute of Oncology IOV-IRCCS, CHU Montpellier,
Abstract
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).Org: Illumina, Inc.,
Abstract
Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02).Org: Memorial Sloan Kettering Cancer Center, New York, NY, Netherlands Cancer Institute, Amsterdam, Netherlands, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice.Org: Invitae, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Mayo Clinic Arizona, Phoenix, AZ, Johns Hopkins University Bloomberg School of Public Health, Cholangiocarcinoma Foundation,
Abstract
Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University College of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Seoul National University Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.Org: MD Anderson Cancer Center, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Mary Crowley Cancer Research Center, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.Org: Beijing Cancer Hospital & Institute, Cancer Hospital of Shantou University Medical College, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Luoyang Center Hospital, Department of Medical Oncology, Zibo Municipal Hospital, Zibo, China,
Abstract
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.Org: Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, Department of Oncology, University of Oxford, Oxford, United Kingdom, Division of Pathology and Data Analytics, University of Leeds, Leeds, United Kingdom, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom, Queen's University Belfast, Belfast, United Kingdom,
Abstract
Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, Resolution Bioscience, Agilent,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Org: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia, Sydney, Australia, Garvan Institute of Medical Research,
Abstract
Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.Org: Tom Baker Cancer Center, Calgary, AB, Canada, Caris Life Sciences, Irving, TX, Irving, TX, Phoenix, AZ,
Abstract
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Roche Products Ltd., F. Hoffmann-La Roche Ltd, Genentech, Centro de Investigación y Manejo del Cáncer (CIMCA),
Abstract
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.Org: mProbe Inc., Stanford University School of Medicine,
Abstract
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.Org: EMD Serono Research & Development Institute, Genesis Research, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center,
Abstract
Racial disparity in the clinical outcomes of HER2-low and HER2-zero early-stage breast cancer.Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY,
Abstract
Cardiac dysfunction (CD) among breast cancer survivors (BCS): Role of cardiotoxic therapy and cardiovascular risk factors.Org: University of Alabama at Birmingham School of Medicine, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Alabama School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology Oncology, UPMC Hillman Cancer Center/University of Pittsburgh,
Abstract
Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.Org: Memorial Sloan Kettering Cancer Center, Hartford Healthcare Medical Group, Hartford Healthcare Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: A systematic review and network meta-analysis.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Department of Molecular Pharmacology and Therapeutics,
Abstract
Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer.Org: Yale-New Haven Health, Yale University School of Medicine,
Abstract
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2-positive breast cancers.Org: Henry Ford Cancer Institute, Detroit, MI, Henry Ford Health System,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study.Org: Beijing Tian Tan Hospital, Capital Medical University, Capital Medical University, Beijing InnoCare Pharma Tech,
Abstract
Time to treatment in inflammatory breast cancer: Experience from a single institution.Org: Ohio State University Wexner Medical Center, Center for Biostatistics in the Department of Biomedical Informatics, The Ohio State University - James Cancer Hospital, Ohio State University Comprehensive Canvcer Hospital,
Abstract
A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ⅰa/Ⅰb, first-in-human, open-label, single-center study.Org: The First Hospital of China Medical University, Shenyang, China, Shenyang Sunshine Pharmaceutical, China National Biotec Group, he First Hospital of China Medical University,
Abstract
Clinicopathologic features of early stage HER2-low breast cancer.Org: Comprehensive Hematology-Oncology, St. Petersburg, FL,
Abstract
Prevalence of low HER2 expression in breast cancer patients: An Indian experience.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Surgical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, Department of Radiation Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital,
Abstract
Pattern of molecular testing among US veterans with gastrointestinal cancers: A single center experience.Org: Veterans Affairs Medical Center, Oklahoma City, OK, Oklahoma City VA Health Care System,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, First Affiliated Hospital of Xi’an Jiaotong University,
Abstract
Real world evidence for continuing HER2-directed therapy for metastatic breast cancer.Org: BC Cancer-Vancouver Centre, B.C. Cancer Agency, University of Toronto, BC Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency,
Abstract
Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center.Org: Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands, Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands, Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands, Radboud University Medical Center, Nijmegen, Netherlands, Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands,
Abstract
Possible advantage of granulocyte colony-stimulating factor in breast cancer chemotherapy during COVID-19 pandemic: A single center experience in Japan.Org: Nagoya Tokushukai General Hospital,
Abstract
Incidence of hypomagnesemia in patients with HER2+ breast cancer treated with pertuzumab.Org: University of Florida College of Medicine Jacksonville, University of Florida/UF Health Cancer Center,
Abstract
Genomic biomarker testing and treatment in advanced NSCLC: Practice patterns and barriers in a global survey of oncology point-of-care mobile app users.Org: Siyemi Learning, ONCOassist, Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom,
Abstract
De novo metastatic Her2+ breast cancer in a diverse population of women under age 40.Org: Ochsner Medical Center, Ochsner Health System, Ochsner Health Center, Ochsner Clinic Foundation,
Abstract
Restaging scans frequency heterogeneity in patients being treated for stage IV non-small cell lung cancer (NSCLC).Org: Mayo Clinic, Jacksonville, FL,
Abstract
Comparing time to treatment for neoadjuvant chemotherapy for breast cancer across the urban-rural continuum.Org: Rush University Medical Center,
Abstract
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group,
Abstract
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.Org: University of Pennsylvania, Department of Medicine (Hematology - Oncology Division), Perelman School of Medicine, University of Pennsylvania,
Abstract
Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.Org: Caris Life Sciences, Irving, TX, West Virginia University Health Sciences Center Department of Epidemiology and Biostatistics, Mayo Clinic, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Incidence of interstitial lung disease and cardiotoxicity with trastuzumab-deruxtecan in patients with breast cancer: A systematic review and single-arm meta-analysis.Org: Federal University of Goiás, Princess Margaret Hospital, Dona Íris Hospital and Maternity,
Abstract
Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a multicenter, prospective study in China.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Affiliated cancer hospital of Guangxi Medical University, Guangxi, China,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Survival in patients with brain metastasis secondary to breast cancer from Saudi Arabia.Org: Faculty of Medicine, Cairo University, King Abdulaziz University, Jeddah, Saudi Arabia,
Abstract
A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.Org: Second Affiliated Hospital of Soochow University, Institution of Radiotherapy & Oncology, Soochow University,
Abstract
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.Org: SAIHST, Sungkyunkwan University of Medicine, Samsung Medical Center,
Abstract
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.Org: Integra Connect PrecisionQ, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists and Research Institute, Ocala, FL, Thermo Fisher Scientific,
Abstract
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patients.Org: Medanta Medicity, Medanta - The Medicity, Medanta- The Medicity, Medanta-The Medicity, Medanta The Medicity,
Abstract
ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer.Org: UC San Diego Moores Cancer Center, Biofluidica, Biomatrica, Inc.,
Abstract
Neoadjuvant endocrine therapy for early-stage breast cancer: An institutional experience during the COVID19 pandemic.Org: Dartmouth-Hitchcock Medical Center, Dartmouth College Geisel School of Medicine, Dartmouth Geisel Medical School Community and Family Medicine,
Abstract
Characterization of patients with recurrent breast cancer submitted to neoadjuvant therapy in a Brazilian cancer center.Org: A.C. Camargo Cancer Center, Hospital ACCamargo, A.C. Camargo Hospital,
Abstract
Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study.Org: University of California, Irvine, Irvine, CA, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Nepal Medical College and Teaching Hospital, Kathmandu Medical College and Teaching Hospital,
Abstract
Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer.Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Juan Ramón Jiménez Hospital,
Abstract
Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer.Org: American Cancer Society, Atlanta Cancer Care, Galderma R&D, Emory University School of Medicine, Roswell Park Comprehensive Cancer Center,
Abstract
Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2‑positive metastatic breast cancer: A phase II trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
In search for new targets: Differences of HER2 receptor expression between CNB and synchronous axillary lymph node metastases in 205 patients.Org: University of Leipzig Medical Center, Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Division of Breast Surgery, Gynecologic and Perinatal Pathology,
Abstract
UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer.Org: David Geffen School of Medicine at University of California Los Angeles, Weizmann Institute of Science,
Abstract
Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions.Org: VA Center for Clinical Management and Research, Yale College, Pritzker School of Medicine, University of Chicago Medicine, Committee on Clinical Pharmacology and Pharmacogenomics,
Abstract
Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03.Org: Kanagawa Cancer Center, Matsuyama Red Cross Hospital, Nagoya University Graduate School of Medicine, Asahikawa Medical University Hospital, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
Subcutaneous versus endovenous trastuzumab: Real world data from a reference cancer center in Peru.Org: Specialized Institute of Neoplastic Diseases Lima, Instituto Nacional de Enfermedades Neoplasicas, Lima, 51, Peru, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, Inst Nac de Enfermedades Neoplas, Lima, Lima, Peru,
Abstract
Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center,
Abstract
Retrospective analysis of Ki-67 as a predictive and prognostic marker for pathological complete response to neoadjuvant chemotherapy in breast cancer.Org: Tata Memorial Centre, BBCI (B Borooah Cancer Institute), Dr Bhubaneswar Borooah Cancer Institute,
Abstract
Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results.Org: Moscow Clinical Scientific Center named after A.S. Loginov, Moscow Oncology City Hospital 62, SBIH Municipal Clinical Oncology Hospital №1 of DHM, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS,
Abstract
No checkmate in metastatic setting: Navigating real world patients applying personalized therapy based on extensive tumor profiling.Org: Datar Cancer Genetics Europe GmbH, Datar Cancer Genetics, Novustat GmbH,
Abstract
FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients.Org: Tempus Labs, Inc., Durham, NC, Statagize LLC, Thousand Oaks, CA, Indapta Therapeutics Inc.,
Abstract
Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer.Org: Fortis Cancer Institute, Rajiv Gandhi Cancer Institute and Research Centre, Tata Memorial Centre, Datar Cancer Genetics, Datar Genetics Limited,
Abstract
Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.Org: Care Across,
Abstract
A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924).Org: Roche Products Limited, Cmed Clinical Research Services, Leeds Institute of Medical Research at St James’s, Kent Oncology Centre, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Kanagawa Cancer Center, Itami City Hospital,
Abstract
Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.Org: BillionToOne, Inc., UC San Diego Moores Cancer Center,
Abstract
T cell redirecting and TLR7/8 agonist encapsulated liposomes targeting HER2+ tumors: Preclinical efficacy, pharmacokinetics and safety evaluations.Org: Hangzhou Highfield Biopharmaceuticals Inc., Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences,
Abstract
Precision medicine applied to rare malignancies: A single-center experience at University Hospital of Verona.Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata di Verona, Investigational Cancer Therapeutics Clinical Unit and Section of Oncology, ARC-Net Research Centre - Diagnostic and Public Health Department, University of Verona - Faculty of Medicine,
Abstract
Combined role of the neutrophil/lymphocyte ratio and Neo-Bioscore in neoadjuvant therapy in HER2-positive early breast cancer.Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Aodo Asociación Onubense Para,
Abstract
De-escalating therapy dilemma in small HER2 positive node negative breast cancer.Org: Centre Oscar Lambret,
Abstract
First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial.Org: Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Yoko Biomedical,
Abstract
Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.Org: West China Hospital, Sichuan University, Breast Disease Center, West China Hospital, Sichuan University, West China Hospital of Sichuan University,
Abstract
Radiotherapy combined with pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases: A single-arm, exploratory trial.Org: Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China, Department of Breast Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China, Department of Breast Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China,
Abstract
Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.Org: Jiangsu Hengrui Pharmaceuticals Co.,Ltd,
Abstract
Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Effect of suppressing the p38 pathway through upregulation of Wip1 on Her2 early dissemination of breast cancer.Org: Wake Forest Baptist Medical Center, Tianjin Medical University Cancer Institute and Hospital,
Abstract
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.Org: The Fifth Medical Centre of Chinese PLA General Hospital, Chinese PLA General Hospital, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, Fujian Medical University Union Hospital,
Abstract
Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort.Org: Taipei Veterans General Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,
Abstract
Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.Org: University of Chicago Medical Center, Chicago, IL, University of Chicago, Department of Medicine, Icahn School of Medicine at Mount Sinai, Section of Hematology & Oncology, University of Illinois Chicago,
Abstract
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Evolution of breast cancer management in the Dominican Republic in the 21st century.Org: FUNDEONCAP, IOHP, Dominican Society of Oncology,
Abstract
Clinicopathological characteristics and outcome of very young breast cancer patients at a referral center in Iran.Org: Shahid Beheshti University of Medical Sciences, Shahid Beheshti Univerity of Medical science,
Abstract
Shifting trends in the usage of trastuzumab with its biosimilar inception in India.Org: Mylan Pharmaceuticals, Viatris,
Abstract
EGFR/ERBB2 aberrations in Chinese biliary tract carcinomas.Org: Eastern Hepatobiliary Surgery Hospital, Shanghai, China, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China, The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China,
Abstract
Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor.Org: BiOneCure Therapeutics, BiOneCure Therapeutics LLC,
Abstract
Area deprivation index and breast cancer subtypes in young patients.Org: Ochsner Medical Center, Ochsner Health System, Ochsner Clinic Foundation, Ochsner Health Center,
Abstract
Prognosis of patients with HER2-low breast cancer brain metastasis: A single-institution experience.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer.Org: Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil,
Abstract
Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers.Org: Hôpital Tenon, Institut Universitaire de Cancérologie, Sorbonne Université, APHP-INSERM U1149 Universite Paris Diderot, Hôpital La Pitié-Salpêtrière,
Abstract
Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients.Org: Biofidelity Ltd,
Abstract
Reflex MammaPrint testing on breast core biopsies: A single center experience.Org: University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Sunnybrook Health Sciences Center,
Abstract
Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer.Org: Moscow Clinical Scientific Center named after A.S. Loginov, Russian Cancer Research Center N.N. Blokhin,
Abstract
Differences of RAS/BRAF mutations between ISCC and RSCC in a Chinese population.Org: the General Hospital of Southern Theater Command，PLA., Guangzhou, China, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases.Org: 3D Medicines Inc.,
Abstract
Reality check for precision oncology in squamous cell lung cancer.Org: UAMS-Winthrop Rockefeller Cancer Institute, UAMS Medical College Physicians Group,
Abstract
Enhanced detection and characterization of targetable EGFR and ERBB2 exon20 insertion mutations in urothelial carcinoma.Org: University of North Carolina School of Medicine, UNC Hosps, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill,
Abstract
A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer.Org: University of California, Irvine, Irvine, CA, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Nepal Medical College and Teaching Hospital, Kathmandu Medical College and Teaching Hospital,
Abstract
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.Org: University of British Columbia, BC Cancer-Vancouver Centre, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer.Org: Mayo Clinic, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, City of Hope National Medical Center, Daiichi Sankyo Inc., Daiichi Sankyo Co. Ltd.,
Abstract
Does community size impact survival with breast cancer? Data from a large population-based cohort in British Columbia.Org: BC Cancer-Vancouver Centre, British Columbia Breast Cancer Outcomes Unit, Breast Cancer Outcomes Unit, BC Cancer Agency Vancouver Island Centre, University of British Columbia,
Abstract
Prognostic stratification and outcome of metastatic NSCLC based on activating mutation profile and PD-L1 status.Org: The University of Texas Health Science Center at Houston, UTHealth Houston, McGovern Medical School,
Abstract
A meta-analysis of cardiac toxicity of concurrent epirubicin and trastuzumab in early breast cancer.Org: National Taiwan University Hospital Hsinchu branch, Hsinchu City, Taiwan Bio Therapeutics, National Taiwan University Hospital Yunlin Branch, National Taiwan University College of Medicine,
Abstract
Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer.Org: Bhaktivedanta Hospital And Research Centre and School of Consciouness, MIT WPU, OneCell Dx, Indx Technology, Artemis Hospital Gurgaon,
Abstract
Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,
Abstract
Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.Org: Fortis Cancer Institute, Sir H N Reliance Foundation Hospital and Research Centre, BALCO Medical Center, Fortis Hospital Mulund, Datar Cancer Genetics,
Abstract
Comparing digital and glass slide methods for determining the HER2-low and negative categories in breast cancer.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer.Org: The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical, Second Hospital of Tianjin Medical University,
Abstract
Oncomine Dx Express CE-IVD liquid biopsy assay for non-small cell lung cancer: Performance review and analytical validation.Org: Thermo Fisher Scientific, Austin Health, Txinno Bioscience,
Abstract
RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, BostonGene, Corp., University of Texas MD Anderson Cancer Center,
Abstract
Breast cancer brain metastases: the Graded Prognostic Assessment index (GPA) in a real-world low- and middle-income (LMIC) population.Org: Instituto Nacional de Cancer - INCA, Instituto Nacional de Câncer (INCA),
Abstract
Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).Org: University of Chicago, Janssen Scientific Affairs, Analysis Group, Inc.,
Abstract
Real-world safety and effectiveness of CT-P6 (biosimilar trastuzumab): A post-marketing surveillance study in Korea.Org: Chonnam National University Hwasun Hospital, Inje University Busan Paik Hospital, Korea University Guro Hospital, Hallym University Sacred Heart Hospital, Korea Cancer Center Hospital,
Abstract
A combination of circulating tumor cell (CTC) and cancer stem cell (CSC) markers to predict the prognosis of breast cancer.Org: Baylor College of Medicine Division of Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Baylor College of Medicine,
Abstract
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).Org: Department of Breast Surgery Osaka Medical and Pharma ceutical University, Osaka Medical and Pharmaceutical University, Department of Rehabilitation Medicine Osaka Medical College, Osaka Medical snd Pharmaceutical University, Osaka Police Hospital,
Abstract
Cost-effectiveness of novel systemic therapies for advanced breast cancer: Global representativeness and influence of funding.Org: Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo/ICESP, São Paulo, SP, Brazil, Sao Paulo State Cancer Institute (ICESP), São Paulo, Brazil,
Abstract
Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer.Org: Daiichi Sankyo Inc., Certara Germany GmbH, Daiichi Sankyo Shinagawa R&D Center, Daiichi Sankyo Europe GmbH,
Abstract
Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: The experience of an academic hospital.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Antwerp University Hospital, University Hospital of Antwerp, Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,
Abstract
Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.Org: Saint Mary's and Saint Clare's Hospital, New York Medical College - Saint Michael's Medical Center, Schulich School of Medicine and Dentistry, BronxCare Health System, Dr. V.R.K. Women’s Medical College,
Abstract
Early integration of exercise into breast cancer care: The MSK Healthy Living program.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).Org: Weill Cornell Medical Center/New York Presbyterian, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Tumor immune microenvironment in BRAF V600E mutant lung adenocarcinoma.Org: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Pekin, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Caner Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of diagnostic radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Genecast Biotechnology Co., Ltd., Wuxi, China,
Abstract
Comprehensive genomic analysis of salivary gland carcinomas in a Chinese population.Org: Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai OrigiMed Co., Ltd, Shanghai, China,
Abstract
Role of plasma circulating HER2/EFTUD2 ratio in predicting pathological complete response (pCR) after neoadjuvant dual anti-HER2 therapy in HER2-positive breast cancer (HER2+ BC).Org: Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong, Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, Hong Kong, Departments of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong, Queen Elizabeth Hospital, Kowloon, Hong Kong, Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong,
Abstract
Breaking down the divide: An analysis of male breast cancer demographics and survival by race.Org: The Wright Center for Graduate Medical Education, University of Texas Health Science Center, Geisinger Health System Department of Pathology,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,
Abstract
Copy number variation (CNV) calling of MET, MYC, and ERBB2 using PiVAT bioinformatic platform.Org: Shanghai Zhengu Biological Technology Co., Ltd, Pillar Biosciences Inc.,
Abstract
Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity.Org: Avera Cancer Institute, Sioux Falls, SD, Theralink Technologies Inc, George Mason University, Manassas, VA,
Abstract
The mutational landscape of circulating cell free DNA in patients with gastric cancer.Org: The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Oncology,Daqing Oilfield Hospotal, Harbin, China, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, HaploX Biotechnology, Shenzhen, China, China-Japan Union Hospital of Jilin University, Jilin, China,
Abstract
Knowledge gaps and educational needs for common cancer therapy-related cardiovascular toxicities and related drug interactions.Org: UNC Eshelman School of Pharmacy, Duke University Medical Center, Baptist Health Systems, North Memorial Hill Health, Baghdad Heart Center,
Abstract
Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes.Org: Delfi Diagnostics, Inc., DELFI Diagnostics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.Org: Linkou Chang Gung Memorial Hospital and Chang Gung University, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Chang Gung Memorial Hospital, Chang Gung University Medical College, Gynecologic Cancer Research Center,
Abstract
HER2 in situ hybridization testing in breast cancer: Applying algorithm-assisted assessment to reduce interobserver variability in difficult cases.Org: Mater Health Services-Mater Research Institute, Mater Research Institute - University of Queensland, Centre for the Business and Economics of Health, University of Queensland, Mater Research Institute-University of Queensland,
Abstract
Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial.Org: First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Anyang Tumor Hospital,
Abstract
Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?Org: Weill Cornell Medicine - Qatar, Doha, Qatar, Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Assessing the real-world experience of treating gastric cancer in Armenia: A retrospective-study.Org: Immune Oncology Research Institute, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center After R.Yeolyan, Hematology center after prof. Yeolyan, Mikaelyan Institute of Surgery,
Abstract
Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,
Abstract
Clinical and molecular characterization of HER2-low metastatic colorectal cancer.Org: Hadassah-Hebrew University Medical Center, Dana-Farber Cancer Institute,
Abstract
Defining the patient population with HER2-low breast cancer in Hawaii.Org: University of Hawaii Cancer Center, John A Burns School of Medicine, Kapiolani Medical Center for Women and Children,
Abstract
Assessing the Discordance Rate of HER2 expression by Immunohistochemistry between Primary and Secondary Prostate Cancer Biopsies.Org: Washington DC Veteran Affairs Medical Center, Washington DC VA Medical Center, The George Washington University School of Medicine and Health Sciences, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, George Washington University Milken Institute School of Public Health,
Abstract
Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries.Org: Fortis Cancer Institute, New Delhi, India, Fortis Cancer Institute, Bangalore Karnataka, India, Fortis Cancer Institute, Gurgaon, Haryana, India, Fortis Cancer Institute, Delhi, India, Fortis Hospital and research centre, New Delhi, India,
Abstract
Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection.Org: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jichenjunchuang Medical Laboratory(Hangzhou), Co. Ltd., Hangzhou, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.Org: CAPESESP,
Abstract
Comparative analysis of the mutation detection using malignant pleural effusion and blood cell-free DNA samples in lung cancer.Org: Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Department of Oncology,The Fourth Hospotal of Heilongjiang Province, Harbin, China, Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hunan, China., Thoracic surgery，Affiliated hospital of Guizhou Medical University, Guiyang, China,
Abstract
Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study.Org: Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea, Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital,
Abstract
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).Org: Cerba Research, Montpellier Cancer Institute, France, Montreal, QC Kinetix,
Abstract
The efficacy and safety of antibody drug conjugate for high-risk non-muscle-invasive bladder cancer.Org: Tianjin Medical University Second Hospital, The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical,
Abstract
Male breast cancer survival data and clinicopathological characteristics: A single-centre experience.Org: Hospital Agios Savvas, Agios Savvas Cancer Hospital, Saint Savvas Hospital, Agios Savvas Anticancer Hospital, Second Department of Medical Oncology,
Abstract
The impact of ImmunoPrecision in small bowel adenocarcinoma.Org: Cedars-Sinai The Angeles Clinic and Research Institute, University of New Mexico Comprehensive Cancer Center, Texas Oncology-Austin Lakeway, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Masonic Cancer Center, University of Minnesota, Minneapolis, MN,
Abstract
The impact of the COVID-19 pandemic on the diagnosis and treatment of breast cancer at a community hospital.Org: Gundersen Health System, La Crosse, WI, Gundersen Medical Center,
Abstract
Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors.Org: Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd., Chinese PLA General Hospital & Medical School, Beijing, China,
Abstract
Anti–PD-1 combination regimen as first-line therapy in advanced biliary tract cancer and biomarker exploration: A retrospective study.Org: The Comprehensive Cancer Centre of Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Department of Radiology of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Department of Pathology of Nanjing Drum Tower Hospital,
Abstract
Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, China Academy of Chinese Medical Sciences,
Abstract
Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) therapy.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China, Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China, Pathology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.Org: University of Padua School of Medicine, Veneto Institute of Oncology IOV-IRCCS Padua, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Department of Oncology, Hematology, and Respiratory Diseases, Modena University,
Abstract
Prognostic effects of TP53 variants co-occuring in patients with HER2-mutated non-small cell lung cancer (NSCLC).Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, University of Toronto,
Abstract
Neoadjuvant therapy (NAT) in early breast cancer (EBC): Results from a prospective observational multicenter BRIDE study.Org: Oncologia Medica - IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella (VR), Italy, IRCCS Regina Elena National Cancer Institute, Division of Medical Oncology 1, Rome, Italy, Roma, Italy, Oncologia - Humanitas Gavazzeni, Bergamo, Italy, Oncologia - Azienda Sanitaria dell’Alto Adige, Bolzano, Italy,
Abstract
Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US).Org: Merck & Co, Inc., Merck & Co., Inc., Merck and Co, Inc.,
Abstract
Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Padua, Italy, Padua, Italy,
Abstract
The impact of novel therapies on disparities in survival outcomes for metastatic cancers.Org: Lumen Value & Access, Healthcare Consultancy Group,
Abstract
Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.Org: University of Modena and Reggio Emilia, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Molecular Pathology Laboratory, Program Clinical and Experimental Medicine,
Abstract
Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience.Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
Deep multi-omic analyses to identify targetable pathways in desmoplastic small round cell tumor (DSRCT) with opportunities for clinical intervention.Org: OHSU Knight Cancer Institute, Portland, OR, Portland, OR, Oregon Health & Science University, Knight Cancer Institute,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,
Abstract
Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.Org: Mayo Clinic, H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic Florida,
Abstract
The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Cincinnati Medical Center, Brown University - Lifespan Cancer Institute, Hoag Family Cancer Institute and University of Southern California,